▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $337.90.
The current consensus among 5 polled investment analysts is to hold stock in Sartorius Stedim Biotech. This rating has held steady since May 2020, when it changed from a Sell consensus rating.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, fluid management services, and membrane chromatography services. In addition, the company offers data analytics software for modeling and optimizing processed of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.